SOSzczepan Olszewski

Szczepan Olszewski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Szczepan Olszewski has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Overactive PDGFRα and PDGFRβ promote distinct phenotypes of skeletal muscle fibrosis and stiffness, with PDGFRβ also driving muscle growth

    by Mariola Gimla, Szczepan Olszewski, Jacob L. Brown, Christiana J. Raymond-Pope, Sandra Rigsby, Frederick F. Peelor, Hae Ryong Kwon, Longbiao Yao, Lorin E. Olson, Jordan D. Fuqua, et al.

    This study demonstrates that overactive PDGFRα and PDGFRβ signaling drive distinct and sex-specific skeletal muscle remodeling phenotypes. Overactive PDGFRα induces robust fibrosis characterized by increased insoluble and cross-linked collagen, elevated LOX and AGE levels, and marked muscle stiffness. Thus, establishing a new model to study skeletal muscle fibrosis. Overactive PDGFRβ unexpectedly promoted skeletal muscle hypertrophy and reduced fat mass with minimal fibrosis, revealing a previously unrecognized role in regulating muscle growth in vivo.


  • Open Access

    Top–Down Proteomics of Skinned Human Muscle Fibers Reveals Proteoform‐Resolved Fiber‐to‐Fiber Variability

    by Mallory C. Wilson, Zhan Gao, Justin R. Lopez, Yanlong Zhu, Szczepan S. Olszewski, Adam R. Konopka, Gary M. Diffee, Ying Ge

    Human skeletal muscle is composed of highly heterogeneous single muscle fibers (multinucleated single cells) that are commonly classified as fast or slow fiber types, yet proteoform‐resolved characterization of individual human muscle fibers remains lacking. Herein, we establish a high sensitivity top–down proteomics method for the analysis of single human muscle fibers (hSMFs). Specifically, we have optimized the surfactant‐free extraction protocol for analysis of chemically permeabilized (“skinned”) hSMFs, a common preparation used to isolate the sarcomere prior to contractile measurements. This approach enables robust and reproducible proteoform‐level coverage of key sarcomeric proteins from individual fibers using top–down LC–MS/MS. With this method, we identified extensive inter‐ and intra‐donor fiber‐to‐fiber variability in isoform expression and proteoform abundance in hSMFs extracted from the heterogeneous vastus lateralis muscles. Together, these results demonstrate the capability of single‐fiber top–down proteomics to resolve proteoform‐level heterogeneity in human skeletal muscle and establish a methodological foundation for future studies towards elucidating skeletal muscle biology and understanding muscle‐related diseases. Source data for this manuscript is available via the MassIVE repository at massive.ucsd.edu with identifier: MSV000100493.


  • N-homocysteinylation of ferritin and associated changes in iron metabolism as potential drivers of vascular endothelial dysfunction in hyperhomocysteinemia

    by Andzelika Borkowska, Ulana Juhas, Szczepan Olszewski, Joanna Reczkowicz, Pawel Wityk, Banu Akdogan, Hans Zischka, Jedrzej Antosiewicz


  • PoWeR elicits intracellular signaling, mitochondrial adaptations, and hypertrophy in multiple muscles consistent with endurance and resistance exercise training

    by Christian J. Elliehausen, Szczepan S. Olszewski, Dennis M. Minton, Audrey L. Spiegelhoff, Carolyn G. Shult, Wenyuan G. Zhu, Troy A. Hornberger, Adam R. Konopka

    Using PoWeR, we evaluated skeletal muscle mitochondrial and hypertrophic adaptions revealing muscle-specific adaptations across fore and hind limbs consistent with endurance and resistance exercise in humans. We present a short-term PoWeR paradigm that identifies muscle-specific signaling responses thought to support long-term adaptions to PoWeR. These data provide further support for PoWeR as a model to resemble the metabolic and anabolic adaptions to endurance and resistance exercise in humans.


  • Open Access

    Iron status determined changes in health measures induced by nordic walking with time-restricted eating in older adults– a randomised trial

    by Jakub Antoni Kortas, Joanna Reczkowicz, Ulana Juhas, Ewa Ziemann, Aleksandra Świątczak, Katarzyna Prusik, Szczepan Olszewski, Nakisa Soltani, Ewa Rodziewicz-Flis, Damian Flis, et al.

    Background and aims: This study evaluated whether stored iron determines the adaptive response induced by Nordic walking (NW) training combined with 10 hours’ time-restricted eating (TRE) in older adults. Trial design and methods: Twenty-four participants underwent 12-week NW training supported by 10 h of TRE. The group was divided due to baseline ferritin concentration low < 75 ng/ml (LF) and high level ≥ 75 ng/ml (HF). Body composition, physical fitness and blood collection were assessed at baseline and post-intervention. Results: NW + TRE induced a statistically significant decrease in ferritin levels in all participants (p = 0.01). Additionally, statistically significant intergroup differences in the LF vs. HF in the reduction of serum ferritin levels (p = 0.04) were observed. The procedure NW + TRE diminished HbA1c levels (p < 0.01) and glucose in all participants (p = 0.05). The range of HbA1c drop was more pronounced among those participants who experienced a greater decrease in the stored iron (p = 0.04, $$ {\eta }_{p}^{2}$$ =0.17, F=4.59). Greater changes in body weight and percent of body fat were recorded in the HF group (for both p<0.01). Conclusion: Body iron stores determine the effects of a 12-week NW + TRE intervention on serum ferritin. The changes in HbA1c are more pronounced in subjects with a higher decrease in serum ferritin. Trial registration: All experimental protocols were approved by the Bioethical Committee of the Regional Medical Society in Gdansk, Poland (NKBBN/330/2021) according to the Declaration of Helsinki. We confirm that all methods were carried out in accordance with relevant guidelines and regulations. The trial was registered as a clinical trial (NCT05229835, date of first registration: 14/01/2022, direct link: https://classic.clinicaltrials.gov/ct2/show/NCT05229835). Informed consent was obtained from all subjects.